구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Elranatamab |
Overview Company | Pfizer |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Multiple Myeloma |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | novel ALPS (Anemia-LDH Prognostic System) score, which stratified patients into distinct risk groups for ORR, OS, PFS, and du |
Positioning Known limitation | resistance to available treatments |
MoA Mechanism | targeting both B-cell maturation antigen |
MoA Biomarker | BCMA-targeted therapies and feasibility in selected high |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin |
Toxicology CRS | 58% |
Clinical Safety signal | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin |
Clinical Selected reported efficacy | ORR 61% |
Clinical Reported ORR | 56.0% |
Clinical Result source | ClinicalTrials.gov NCT05565391 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT05565391 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Elranatamab |
Overview Company | Pfizer |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Multiple Myeloma |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | novel ALPS (Anemia-LDH Prognostic System) score, which stratified patients into distinct risk groups for ORR, OS, PFS, and du |
Positioning Known limitation | resistance to available treatments |
MoA Mechanism | targeting both B-cell maturation antigen |
MoA Biomarker | BCMA-targeted therapies and feasibility in selected high |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin |
Toxicology CRS | 58% |
Clinical Safety signal | Hepatotoxicity : Can cause elevated ALT, AST, and bilirubin |
Clinical Selected reported efficacy | ORR 61% |
Clinical Reported ORR | 56.0% |
Clinical Result source | ClinicalTrials.gov NCT05565391 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT05565391 |
추천 비교
추천 비교